Summary
CJC-1295 and Sermorelin sit closest together within the GHRH analog, which gives them a broadly related biological identity. Both are most often discussed in Metabolic and endocrine and Aging and longevity, which gives the comparison a meaningful common setting even when the rest of their profiles are not identical. Mechanistically, both point toward Receptor agonist and converge on Growth hormone axis, although the downstream emphasis is not identical. Both are synthetic in origin and their development context also differs, with CJC-1295 in Preclinical development while Sermorelin is approved. CJC-1295 takes the form of a peptide conjugate, whereas Sermorelin is closer to a linear peptide, while CJC-1295 carries d-amino acid substitution features, while Sermorelin instead reflects amidation changes.